Matricelf Ltd
TASE:MTLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Matricelf Ltd
Capital Expenditures
Matricelf Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Capital Expenditures
-₪243k
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Capital Expenditures
-$9.8m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Capital Expenditures
-$95k
|
CAGR 3-Years
76%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-12%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Capital Expenditures
-$289k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Capital Expenditures
-$83k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Capital Expenditures
-$1.9m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-1%
|
|
Matricelf Ltd
Glance View
Matricelf Ltd. engages in research and development of technology in the field of regenerative medicine. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
See Also
What is Matricelf Ltd's Capital Expenditures?
Capital Expenditures
-243k
ILS
Based on the financial report for Dec 31, 2024, Matricelf Ltd's Capital Expenditures amounts to -243k ILS.
What is Matricelf Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 3Y
53%
Over the last year, the Capital Expenditures growth was 61%. The average annual Capital Expenditures growth rates for Matricelf Ltd have been 53% over the past three years .
